Cormica Publishes FDA Compounding Enforcement Roadmap

Recurring Form 483 observations in aseptic processing, cleaning validation, and CAPA are driving a sharper enforcement posture across the US compounding sector, and Cormica TPM has published a peer-reviewed analysis mapping the compliance gaps most likely to draw FDA attention. The paper, The Compounding Enforcement Wave: Drivers, Deficiencies, and a Quality System Roadmap for 503A and 503B Facilities, appears in Advances in Chemical Engineering and Science and draws on FDA enforcement records to identify the structural weaknesses regulators are finding repeatedly.

The analysis centres on the regulatory distinction between 503A compounding pharmacies and 503B outsourcing facilities, a divide that carries significant compliance consequences. 503B facilities operate under mandatory cGMP requirements codified in 21 CFR Parts 210 and 211, while 503A pharmacies face a different but increasingly scrutinised framework. For QA directors managing either category, the paper provides a structured view of where enforcement records cluster and which control systems are most frequently cited.

The authors identify eight recurring deficiency areas: aseptic processing and environmental monitoring; sterility assurance and beyond-use date justification; cleaning validation; investigations and CAPA; API sourcing and supplier controls; labelling; and adverse event reporting. Each maps to specific CFR requirements, giving regulatory affairs leads a traceable reference for gap assessments ahead of inspection cycles. Stability study design and beyond-use dating methodology receive particular attention, reflecting FDA's sustained focus on data integrity in compounded preparations.

For plant heads and QA teams, the practical read is around inspection readiness. The paper's framing as a quality system roadmap rather than a regulatory summary positions it as a tool for internal audit programmes, not just background reading. Cormica's laboratory network supports several of the testing activities the paper references, including sterility and bacterial endotoxin testing, cleaning validation studies, container closure integrity testing, and analytical method validation, though the published analysis itself is independent of those service lines.

The paper was authored by scientists at Cormica TPM, including General Manager Dr Kishore Hotha, who brings more than 20 years of international regulatory experience and has supported over 100 regulatory submissions.

As FDA enforcement activity in the compounding sector continues to build, facilities that have not conducted a structured review against the deficiency categories identified in this analysis face measurable inspection risk entering the next audit cycle.

Source: Cormica Pharma & Med Device Testing via cormica.com, 27 August 2026.